As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Content to be used in accordance with local CPO guidelines
Dabrafenib, Alone or in Combination with Trametinib, in Pediatric Patients with BRAF V600 Mutation–Positive Langerhans Cell Histiocytosis
Presentation # 3618 – Poster
December 13, 2021 | 06:00 PM EST